‘How can Artificial Intelligence impact the pharmaceutical drug discovery process?’ This was the debate which Professor Jackie Hunter, CEO of BenevolentBio, led at PiR’s Senior Executive Breakfast forum at the Royal Society of Chemistry in Burlington House on 14 June.
Professor Hunter inspired and provoked the delegates, CEOs and senior executives from the life science industry, to consider how AI could positively disrupt the current drug discovery model.
She reminded us that it costs c$1.5bn to bring a drug to market and that only 1-5% of these make it to market. This model has remained unchanged for decades.
A full summary of the event will appear in PharmaTimes in September 2017.
Carolyn Douthwaite, Founder & Non Executive Chair
Monday 19 June 2017
Feedback on PiR’s Event:
“I found the meeting incredibly useful and made some good inroads with contacts in the AI space. An excellent event, one of the best I’ve been to in last year.”
“Excellent format, very engaging and a good mix of attendees.”
“Good choice of subject – a new and growing area of the industry.”
“Excellent event – very interesting and topical subject, important across many disciplines.”